中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
1期
1-3
,共3页
哮喘%组织型纤溶酶原激活物%尿纤溶酶原激活物%纤溶酶原激活物抑制剂1
哮喘%組織型纖溶酶原激活物%尿纖溶酶原激活物%纖溶酶原激活物抑製劑1
효천%조직형섬용매원격활물%뇨섬용매원격활물%섬용매원격활물억제제1
Asthma%Tissue plasminogen activator,Urinary plasminogen activator%Plasminogen activator inhibitor-1
目的 探讨纤维蛋白溶解酶原激活物抑制剂(PAI)-1、组织型纤维蛋白溶解酶原激活物(t-PA)、尿激酶型纤维蛋白溶解酶原激活物(u-PA)及其受体(u-PAR)在支气管哮喘(简称哮喘)患者诱导痰中的表达及意义.方法 用ELISA法分别检测29例哮喘急性发作者(发作组)、26例缓解者(缓解组)及15例健康对照者(对照组)诱导痰中PAI-1、t-PA、u-PA和u-PAR的含量,同期测定肺功能(第1秒用力呼气容积占预计值百分比,FEV1%pred),并进行比较.结果 发作组和缓解组诱导痰PAI-1、u-PAR 含量[分别为(23.32±21.64)、(0.766±0.272)μg/L和(17.23±9.40)、(0.700±0.271)μg/L]较对照组[(5.99±5.04)、(0.516±0.197)μg/L]均明显升高(P＜0.05).而三组诱导痰uPA、t-PA 含量[分别为(0.287±0.235)、(7.68±3.46)μg/L,(0.251±0.276)、(9.88±4.68)μg/L,(0.239±0.322)、(10.35±7.47)μg/L]比较差异均无统计学意义(P＞0.05).缓解组诱导痰PAI-1与FEV,%pred 呈负相关(r=0.756,P＜0.01).缓解组诱导痰PAI-1与病程呈正相关r=0.454,P＜0.05).结论 PAI-1、u-PAR参与了哮喘气道慢性炎性反应的病理生理过程.
目的 探討纖維蛋白溶解酶原激活物抑製劑(PAI)-1、組織型纖維蛋白溶解酶原激活物(t-PA)、尿激酶型纖維蛋白溶解酶原激活物(u-PA)及其受體(u-PAR)在支氣管哮喘(簡稱哮喘)患者誘導痰中的錶達及意義.方法 用ELISA法分彆檢測29例哮喘急性髮作者(髮作組)、26例緩解者(緩解組)及15例健康對照者(對照組)誘導痰中PAI-1、t-PA、u-PA和u-PAR的含量,同期測定肺功能(第1秒用力呼氣容積佔預計值百分比,FEV1%pred),併進行比較.結果 髮作組和緩解組誘導痰PAI-1、u-PAR 含量[分彆為(23.32±21.64)、(0.766±0.272)μg/L和(17.23±9.40)、(0.700±0.271)μg/L]較對照組[(5.99±5.04)、(0.516±0.197)μg/L]均明顯升高(P＜0.05).而三組誘導痰uPA、t-PA 含量[分彆為(0.287±0.235)、(7.68±3.46)μg/L,(0.251±0.276)、(9.88±4.68)μg/L,(0.239±0.322)、(10.35±7.47)μg/L]比較差異均無統計學意義(P＞0.05).緩解組誘導痰PAI-1與FEV,%pred 呈負相關(r=0.756,P＜0.01).緩解組誘導痰PAI-1與病程呈正相關r=0.454,P＜0.05).結論 PAI-1、u-PAR參與瞭哮喘氣道慢性炎性反應的病理生理過程.
목적 탐토섬유단백용해매원격활물억제제(PAI)-1、조직형섬유단백용해매원격활물(t-PA)、뇨격매형섬유단백용해매원격활물(u-PA)급기수체(u-PAR)재지기관효천(간칭효천)환자유도담중적표체급의의.방법 용ELISA법분별검측29례효천급성발작자(발작조)、26례완해자(완해조)급15례건강대조자(대조조)유도담중PAI-1、t-PA、u-PA화u-PAR적함량,동기측정폐공능(제1초용력호기용적점예계치백분비,FEV1%pred),병진행비교.결과 발작조화완해조유도담PAI-1、u-PAR 함량[분별위(23.32±21.64)、(0.766±0.272)μg/L화(17.23±9.40)、(0.700±0.271)μg/L]교대조조[(5.99±5.04)、(0.516±0.197)μg/L]균명현승고(P＜0.05).이삼조유도담uPA、t-PA 함량[분별위(0.287±0.235)、(7.68±3.46)μg/L,(0.251±0.276)、(9.88±4.68)μg/L,(0.239±0.322)、(10.35±7.47)μg/L]비교차이균무통계학의의(P＞0.05).완해조유도담PAI-1여FEV,%pred 정부상관(r=0.756,P＜0.01).완해조유도담PAI-1여병정정정상관r=0.454,P＜0.05).결론 PAI-1、u-PAR삼여료효천기도만성염성반응적병리생리과정.
Objective To detect the levels of plasminogen activator inhibitor(PAI)-1,tissue plasminogen activator(t-PA),urokinase-type plasminogen activator(u-PA)and urokinase-type plasminogen activator receptor(u-PAR)in induced sputum in patients with asthma and analyze their clinical significances in pathogenesis of asthlna.Methods The induced sputum was isolated from 15 normal subjects(control group),29 patients with acute attack of asthma(attack group)and 26 stable asthma patients(stable group).The levels of PAl-1,t-PA,u-PA and u-PAR were measured by ELISA.Meanwhile FEV1%pred of all groups were evaluated.Results The levels of PAI-1 and u-PAR of induced sputum were significandy higher in at-tack group[(23.32±21.64),(0.766±0.272)μg/L]and stable group[(17.23±9.40),(0.700±0.271)μg/L]than those in control group[(5.99±5.04),(0.516±0.197)μg/L](P＜0.05).As for the induced sputum concentrations of u-PA and t-PA,there were no significant differences among the attack group[(0.287±0.235),(7.68±3.46)μg/L],stable group[(0.251±0.276),(9.88±4.68)μg/L]and control group[(0.239±0.322),(10.35±7.47)μg/L].In stable group,the level of PAI-1 had a negative correlation with the FEV1%pred(r=-0.756,P＜0.01).In stable group,the level of PAI-1 had a positive correlation with the length of disease course(r=0.454,P＜0.05).Conclusion PAI-1 and u-PAR maybe involved in pathophysiologic change of asthma.
